Santé log

Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors

In February 2024, AlphaMedix™ was designated as a breakthrough therapy by the US Food and Drug Administration in RLT-naïve patients with unresectable or metastatic GEP-NETs, recognizing the potential ...
Santé log

Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio

Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts have been accepted for presentation at ...
Santé log

Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose

Efluelda/Fluzone High-Dose also provided superior protection, compared to standard-dose influenza vaccines*, against hospitalizations due to pneumonia or influenza, hospitalizations caused by ...
Santé log

Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment

IMvigor011 is the first global phase III study to read out pioneering a ctDNA- guided approach to post-surgery treatment in muscle-invasive bladder cancer Basel, 20 October 2025 - Roche (SIX: RO, ROG; ...
Santé log

FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis

Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study2 Lupus nephritis affects more than 1.7 ...
Santé log

Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress

Avacta continues to enroll patients in the Phase 1b expansion cohorts with data in salivary gland cancer anticipated by the end of 2025.
Santé log

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

RAPT will host a webcast conference call accompanied by a slide presentation on Monday, October 20, 2025 at 8:30 a.m. ET. To join the conference call via phone and participate in the live Q&A session, ...
Santé log

Subcutaneous RYBREVANT® (amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and ...

New findings from this investigational study build on the strength of the data for amivantamab in non-small cell lung cancer and broadens its potential across additional solid tumours 1,2 “Patients ...
Santé log

PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer

Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium ( 177 Lu) vipivotide tetraxetan) data from the Phase III PSMAddition trial in a Presidential Symposium at the European Society ...
Santé log

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

The analysis of acral melanoma patients from the IGNYTE clinical trial showed treatment with RP1 combined with nivolumab resulted in an objective response rate of 44% (8/18) with a median duration of ...
Santé log

Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch

Revenue growth for the September 2025 quarter compared with the June 2025 quarter was driven by a 66% increase in Ryoncil ® gross sales to US$21.9 million and 69% increase in net sales to US$19.1 ...
Santé log

AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer

The data represent the first clinical trial results of a 212Pb-based PSMA therapy. The findings support the further development of 212Pb-ADVC001 and may offer a new reference point in the treatment ...